Compare Quest Diagnostics Inc (DGX) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Upwork Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Upwork Inc trades at $8.6 (market cap $1.07B). The key difference: Quest Diagnostics Inc is far larger — about 23.8× Upwork Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Upwork Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Upwork Inc for 38 Days on average.
| DGX | UPWK | |
|---|---|---|
Market Cap | $25.48B | $1.07B |
Volume | 941,866 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $247.45 | $22.11 |
52-Week Low | $173.49 | $7.84 |
Typical Hold Time | 56 Days | 38 Days |
Enterprise Value | $31.23B | $833.01M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Upwork (UPWK) trades at $8.60, up 2.38% today, with a bearish technical signal despite recent earnings beat. The stock shows strong fundamentals with 77.21% gross margins and 12.93% net income margin, though revenue growth has stalled at $788M in 2025. Recent insider selling and ongoing securities fraud investigations create headwinds, while institutional buying from Bank of America provides some support. Technical indicators show resistance at $9 and support at $8.
The stock presents a mixed outlook with attractive valuation metrics (P/E 10.99, P/S 1.48) but faces significant AI disruption risks and declining active clients. Analyst consensus leans bullish with $9.64 price target, though near-term challenges from weak guidance and legal scrutiny may limit upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
